Biotech entity
Of the tracked stories, 2 of 4 also mention Compass Pathways, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 3 of those 4, with the remainder spread across 1 other category. Each story carries 2.3 original sources on average, compared with 3.6 for the broader beat in this window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 75 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention Compass Pathways, the most common co-covered peer. Coverage clusters in clinical-trial, which accounts for 3 of those 4, with the remainder spread across 1 other category. Each story carries 2.3 original sources on average, compared with 3.6 for the broader beat in this window. The 25-day window averages about 1.1 stories each week. Their average consequence score of 6.5 runs above the beat's 6 for that window. This profile follows 4 Biotech stories mentioning Psilocybin across the period from February 21, 2026 to March 17, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 288 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Psilocybin. Shared-story counts are live from our verified record — not editorial picks.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
SAP Expansion
Canada amends the Special Access Program to include restricted psychedelic substances.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.
Psilocybin is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
